Joseph W. LaPlume
Net Worth
Last updated:
What is Joseph W. LaPlume net worth?
The estimated net worth of Mr. Joseph W. LaPlume is at least $22,593,340 as of 10 May 2024. He owns shares worth $3,691,574 as insider, has earned $13,251,086 from insider trading and has received compensation worth at least $5,650,680 in Charles River Laboratories International, Inc..
What is the salary of Joseph W. LaPlume?
Mr. Joseph W. LaPlume salary is $941,780 per year as Corporation Executive Vice President of Corporation Devel. & Strategy in Charles River Laboratories International, Inc..
How old is Joseph W. LaPlume?
Mr. Joseph W. LaPlume is 51 years old, born in 1974.
What stocks does Joseph W. LaPlume currently own?
As insider, Mr. Joseph W. LaPlume owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Charles River Laboratories International, Inc. (CRL) | Corporation Executive Vice President of Corporation Devel. & Strategy | 23,276 | $158.6 | $3,691,574 |
What does Charles River Laboratories International, Inc. do?
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Joseph W. LaPlume insider trading
Charles River Laboratories International, Inc.
Mr. Joseph W. LaPlume has made 25 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,304 units of CRL stock worth $295,969 on 10 May 2024.
The largest trade he's ever made was exercising 15,418 units of CRL stock on 15 May 2020. As of 10 May 2024 he still owns at least 23,276 units of CRL stock.
Charles River Laboratories International key executives
Charles River Laboratories International, Inc. executives and other stock owners filed with the SEC:
- Mr. David Ross Smith (59) Corporation Executive Vice President & Chief Financial Officer
- Mr. James C. Foster (74) Chairman, Chief Executive Officer & Pres
- Mr. Joseph W. LaPlume (51) Corporation Executive Vice President of Corporation Devel. & Strategy
- Mr. William D. Barbo (64) Chief Commercial Officer & Corporation Executive Vice President
- Ms. Birgit Girshick (55) Corporation Executive Vice President & Chief Operating Officer